Lucis raises €17.1M Series A to make preventive health a default, not a privilege

Paris-based Lucis has raised a €17.1 million ($20 million) Series A led by Singular, with participation from General Catalyst and Y Combinator, alongside a roster of operator-angels. Coming six months after a €7.2 million seed in December 2025, the round takes the preventive-health startup's total funding to roughly €24 million.

From biomarkers to behaviour

Lucis analyses more than 110 blood biomarkers and feeds the results into an AI-driven, physician-reviewed companion app that turns lab data into specific, personalised guidance — the idea being to catch what an annual check-up misses, before symptoms appear. Founded in 2025 by Maxime Berthelot (CEO) and Baptiste Debever, the company says it has passed 10,000 users across France, the UK, Ireland and Portugal, run more than a million biomarker tests, and built a team of around 20.

The early outcome data is the part investors will have weighed most. Lucis reports that 75% of users followed for six months improved at least three biomarkers without medication — a behavioural, non-pharmaceutical result, which is exactly the kind of evidence preventive health usually struggles to produce.

A genuine, un-inflated Series A

The raise is notable for what it is not: an AI megadeal. In a quarter where Europe's seed and Series A counts fell sharply and a single billion-dollar round flattered the averages, a €17 million Series A into a consumer-health company is the kind of ordinary, mid-sized early-stage deal that has become conspicuously rarer.

The new capital funds European expansion — Lucis is targeting Spain, Germany and Italy by the end of 2026 — and continued development of the companion app. The wager is straightforward, if hard: that prevention can be packaged, subscribed to, and made the default rather than the privilege of those who already think to ask.